BioLineRx

BioLineRx Interest Coverage

Interest Coverage Ratio of BioLineRx (BLRX) as of Oct 19, 2026.

Interest Coverage

-

Last updated:

Interest Coverage Ratio of BioLineRx is 2026 - . Interest Coverage Ratio of BioLineRx was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioLineRx Stock analysis

What does BioLineRx do? BioLineRx Ltd. is a biopharmaceutical company based in Hevel Modi'in, Israel, developing therapeutics for oncology and rare diseases. Its pipeline includes GLIX1 for glioblastoma and other cancers, APHEXDA for sickle cell disease and pancreatic cancer, and BL-5010 for non-surgical skin lesion removal. The company, incorporated in 2003, is listed on the market since 2011 and employs 20 people. BioLineRx is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioLineRx stock

On Eulerpool you can find the complete historical development of Interest Coverage Ratio BioLineRx since 2006 – with annual values, charts, and detailed analysis.

The Interest Coverage ratio measures a company's ability to pay interest on its debt. Higher ratios indicate greater financial strength and lower default risk.

Interest Coverage = EBIT / Interest Expense

A 'good' varies by industry and company stage. On Eulerpool, you can compare Interest Coverage Ratio's BioLineRx with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — BioLineRx

All Key Metrics — BioLineRx